Stress Hyperglycemia Beyond Diabetes: Emerging Concepts

Abstract

Stress hyperglycemia describes a transient elevation in blood glucose levels occurring in the context of acute physiological stress, such as severe illness or trauma, in individuals without pre-existing diabetes. Traditionally considered a benign adaptive response, recent evidence has linked stress hyperglycemia to adverse outcomes across multiple clinical settings, regardless of diabetes status. This review synthesizes current understanding of the epidemiology, mechanisms, risk factors, clinical presentation, diagnostic challenges, therapeutic strategies, and emerging advances in stress hyperglycemia, with a focus on its pathophysiological underpinnings and practical implications for clinicians. We highlight recent guideline recommendations and underscore the importance of individualized care to mitigate potential harms associated with both hyperglycemia and its management in acutely ill patients.

Introduction

Acute hyperglycemia is a frequent metabolic derangement observed in hospitalized patients, notably those with critical illness, sepsis, myocardial infarction, stroke, trauma, or major surgery. While chronic hyperglycemia is a hallmark of diabetes mellitus, stress hyperglycemia occurs even in those with previously normal glucose metabolism. Its occurrence often reflects a complex neuroendocrine and inflammatory response to stress, conferring both adaptive and maladaptive consequences. Over the past decade, mounting data have challenged the notion that stress hyperglycemia is uniformly benign, revealing associations with increased morbidity and mortality in diverse patient populations. This review aims to provide clinicians with a comprehensive, evidence-based overview of stress hyperglycemia beyond the context of diabetes, emphasizing mechanisms, clinical relevance, and evolving management paradigms.

Epidemiology / Disease Burden

Stress hyperglycemia is common among hospitalized patients, with prevalence estimates ranging from 20% to 50% in intensive care units and up to 30% in general wards. The incidence varies by patient population and illness severity. For example, in acute myocardial infarction, up to one-third of non-diabetic patients develop stress hyperglycemia. Studies have consistently demonstrated that stress hyperglycemia is an independent predictor of adverse outcomes, including increased infection rates, prolonged hospitalization, higher rates of organ dysfunction, and increased mortality. Notably, these risks are evident even after adjusting for illness severity and baseline glycemic status, underscoring the clinical burden of this entity beyond diabetes.

Pathophysiology

The pathogenesis of stress hyperglycemia involves a coordinated neuroendocrine cascade triggered by acute illness. Key mediators include elevated levels of counter-regulatory hormones (cortisol, catecholamines, growth hormone, glucagon), pro-inflammatory cytokines (e.g., TNF-α, IL-6), and increased hepatic gluconeogenesis. Simultaneously, there is a reduction in peripheral glucose uptake due to stress-induced insulin resistance. Additional mechanisms include impaired pancreatic β-cell function and altered glucose transport. Recent research implicates mitochondrial dysfunction, adipose tissue lipolysis, and dysregulated incretin responses. Collectively, these alterations serve to mobilize energy substrates for vital organs but may precipitate cellular injury if hyperglycemia is excessive or prolonged.

Risk Factors

Several factors predispose individuals to stress hyperglycemia, including advanced age, obesity, pre-existing impaired glucose tolerance, higher severity of illness, use of glucocorticoids or vasopressors, and underlying chronic comorbidities such as cardiovascular or renal disease. Among children, stress hyperglycemia is particularly notable in those with severe infections or trauma. Genetic polymorphisms affecting stress response pathways and insulin signaling may also modulate susceptibility. Importantly, the risk of stress hyperglycemia increases with the intensity and duration of the precipitating insult.

Clinical Features

Unlike chronic hyperglycemia, stress hyperglycemia is characterized by acute, reversible elevations in blood glucose, often without classic symptoms of diabetes. Clinical manifestations are typically overshadowed by the underlying critical illness. Hyperglycemia may contribute to osmotic diuresis, electrolyte disturbances, and impaired immune function, but these symptoms are nonspecific. The clinical significance lies largely in its correlation with poor outcomes, including increased risk of infections, impaired wound healing, thromboembolic events, and multi-organ dysfunction. Emerging evidence suggests that stress hyperglycemia may also exacerbate neuronal injury in acute stroke and myocardial damage in acute coronary syndromes.

Diagnosis

Diagnosing stress hyperglycemia requires careful distinction from undiagnosed diabetes. Current criteria define stress hyperglycemia as random blood glucose > 140 mg/dL (7.8 mmol/L) in the setting of acute illness in a patient with no prior history of diabetes and normal glycated hemoglobin (HbA1c) levels (<6.5%). In practice, serial glucose monitoring is essential, and measurement of HbA1c upon admission can help differentiate stress-induced from chronic hyperglycemia. However, interpretation may be confounded by acute blood loss, hemolysis, or recent transfusion. Point-of-care capillary glucose testing is widely used for rapid assessment, but laboratory confirmation is recommended for clinical decision-making.

Treatment & Management

The primary goal of managing stress hyperglycemia is to avoid the deleterious effects of both hyperglycemia and iatrogenic hypoglycemia. Insulin therapy is the mainstay of treatment, with intravenous insulin infusions preferred in critically ill patients, allowing for rapid titration. Current guidelines recommend initiating insulin at a threshold of >180 mg/dL (10 mmol/L), with a target range of 140-180 mg/dL (7.8-10 mmol/L) for most critically ill adults. For non-critically ill patients, subcutaneous insulin regimens are commonly employed. Frequent glucose monitoring is paramount. Importantly, aggressive glucose lowering has been associated with increased hypoglycemic events and mortality, prompting a shift towards more moderate glycemic targets. Non-insulin antihyperglycemic agents are generally avoided in the acute setting due to unpredictable pharmacokinetics and risk of adverse events.

Recent Advances / Emerging Therapies

Recent advances in glucose monitoring, including continuous glucose monitoring (CGM) systems, offer the potential for improved glycemic control and early detection of dysglycemia in hospitalized patients. Research is ongoing into the use of incretin-based therapies and SGLT2 inhibitors in acute care settings, though current evidence is insufficient to recommend routine use. Biomarkers such as the stress hyperglycemia ratio (SHR), which compares admission glucose to estimated average glucose from HbA1c, have been proposed as more sensitive predictors of adverse outcomes than absolute glucose levels alone. Machine learning algorithms are being developed to identify high-risk patients and guide individualized glycemic management. Further studies are needed to validate these approaches and determine their impact on clinical outcomes.

Guideline Recommendations

Major professional societies, including the American Diabetes Association (ADA), Society of Critical Care Medicine (SCCM), and the Endocrine Society, provide consensus guidelines for inpatient glycemic management. Key recommendations include screening all acutely ill patients for hyperglycemia, prompt initiation of insulin therapy for persistent elevations >180 mg/dL, and targeting a glucose range of 140-180 mg/dL in most critically ill patients. Individualization of glycemic targets is advised based on comorbidities, risk of hypoglycemia, and overall prognosis. Routine use of oral hypoglycemic agents is discouraged in the acute care setting. Ongoing education and protocol-driven care are emphasized to optimize safety and efficacy.

Conclusion

Stress hyperglycemia in the absence of diabetes is a clinically significant phenomenon associated with increased morbidity and mortality across a spectrum of acute illnesses. Understanding its complex pathophysiology, risk factors, and implications for patient outcomes is essential for clinicians involved in acute and critical care. Emerging evidence challenges the traditional view of stress hyperglycemia as a harmless adaptive response, underscoring the need for vigilant screening and judicious management. Advances in monitoring, risk stratification, and individualized therapy hold promise for improving outcomes, but must be balanced against the risks of overtreatment. Continued research and adherence to evolving guidelines are crucial to optimizing care for patients experiencing stress-induced hyperglycemia.